Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18702133 | 0.77 | HSD11B1 (0.44) | EPHX2RIPK1HSD11B1 | |
| SCHEMBL21137552 | 0.77 | HSD11B1 (0.41) | EPHX2RIPK1HSD11B1 | |
| SCHEMBL21991871 | 0.75 | HSD11B1 (0.46) | EPHX2RIPK1HSD11B1 | |
| SCHEMBL12208870 | 0.75 | EPHX2 (0.33) | EPHX2MEN1KMT2ARIPK1HSD11B1 | |
| SCHEMBL21358370 | 0.75 | USP2 (0.44) | EPHX2 | |
| SCHEMBL18702002 | 0.73 | EPHX2 (0.35) | EPHX2MEN1KMT2ARIPK1 | |
| SCHEMBL17886961 | 0.73 | MEN1 (0.34) | EPHX2MEN1KMT2ARIPK1 | |
| SCHEMBL21358307 | 0.73 | — | — | |
| SCHEMBL20469388 | 0.72 | VNN1 (0.40) | EPHX2 | |
| SCHEMBL31575292 | 0.72 | LMNA (0.40) | EPHX2RIPK1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | EPHX2 1398/4885MEN1 4876/4885KMT2A 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.